Recro Pharma, Inc. (NASDAQ:REPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The brokerage currently has a $8.25 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 12.09% from the stock’s previous close.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Several other research firms also recently weighed in on REPH. Piper Jaffray Companies set a $11.00 target price on Recro Pharma and gave the company a “buy” rating in a research report on Tuesday, July 25th. Roth Capital set a $20.00 target price on Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Janney Montgomery Scott downgraded Recro Pharma from a “buy” rating to a “fair value” rating and dropped their target price for the company from $21.00 to $6.50 in a research report on Wednesday, June 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Recro Pharma presently has a consensus rating of “Buy” and an average target price of $13.82.

Shares of Recro Pharma (NASDAQ REPH) opened at 7.36 on Wednesday. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $10.85. The firm’s 50 day moving average is $7.39 and its 200 day moving average is $7.65. The stock’s market capitalization is $140.24 million.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.90 million. Recro Pharma had a negative return on equity of 55.59% and a negative net margin of 46.75%. Equities analysts expect that Recro Pharma will post ($2.35) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/recro-pharma-inc-reph-rating-increased-to-buy-at-zacks-investment-research/1493188.html.

In other news, insider James E. Flynn sold 110,447 shares of Recro Pharma stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $6.39, for a total value of $705,756.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder James E. Flynn sold 10,000 shares of Recro Pharma stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $6.74, for a total value of $67,400.00. The disclosure for this sale can be found here. Insiders sold a total of 215,762 shares of company stock valued at $1,430,830 in the last quarter. Company insiders own 21.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Recro Pharma by 14.2% in the second quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock valued at $4,501,000 after buying an additional 79,520 shares during the last quarter. OxFORD Asset Management LLP boosted its position in shares of Recro Pharma by 364.3% in the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after buying an additional 159,619 shares during the last quarter. Northern Trust Corp boosted its position in shares of Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after buying an additional 144,676 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Recro Pharma during the first quarter valued at about $1,601,000. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of Recro Pharma during the first quarter valued at about $1,601,000. Institutional investors and hedge funds own 63.71% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.